The Chemical Biology Core (CBC) offers Moffitt Cancer Center (MCC) members access to state-of-the-art technology, instruments, expertise and infrastructure necessary for studying proteins involved in tumorigenesis. The CBC also provides synthetic and medicinal chemistry services for synthesizing chemical probes and to develop lead candidates into compounds that are suitable for pre-clinical cancer efficacy and safety studies.
The specific aims of the CBC are to: 1) assist in study design, implementation of synthesis of chemical probes, X-ray crystallography, and protein production via consultation and collaborations; 2) provide members with resources to study the structure of proteins involved in tumorigenesis; and 3) provide access and training on state-of-the-art instrumentation to members. The CBC is composed of two highly specialized sections, Chemistry and Protein Crystallography, which provide services in Synthetic/Medicinal Chemistry, Protein Crystallography, and Biochemistry. The CBC employs five experienced full-time staff, who provide expertise in chemistry, drug discovery and development, protein production, crystallography and biochemistry, and cancer biology. Chemistry services offered by the CBC include: 1) synthesis of focused libraries for hit-to-lead-optimization of new anti-cancer compounds; 2) synthesis of complex small molecules as chemical probes; 3) medicinal chemistry and scale-up synthesis, to provide pre-clinical compounds for potency, selectivity, efficacy and safety studies; 4) analytical chemistry services, to determine physicochemical properties of potent compounds; 5) and synthesis of tagged chemical probes for affinity-based chemical proteomics studies. The CBC also provides support for cloning, expression, large-scale purification of target proteins, X-ray crystallography, high-resolution structure determination, structure-guided synthesis, protein-protein and protein-ligand/drug interactions, and structure of protein-inhibitor complexes. Facilitating this work, the CBC provides members access to high-end instrumentation and associated training. Over the past five years, chemistry, protein production, and crystallography services have supported the projects of 49 members, including services critical for 14 new research grant awards to members. The CBC contributed to 52 publications via synthesis of compounds, protein production, and high-end instrumentation, and core staff were co-authors on the publications of 24 members. During the most recent fiscal year, the CBC provided service for 23 members in four research programs: CBMM (12 members), CBE (6), IMM (3), and CE (2). Regarding use of the CBC, 81% was by peer-review-funded members. The CBC also provided preliminary data, technical sections, and consultation for 21 research proposals during the most recent year. The CBC is supported by institutional and CCSG funds and will continue to provide outstanding chemical biology and state-of-the-art technologies to MCC members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA076292-19
Application #
9209815
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Project Start
Project End
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
19
Fiscal Year
2017
Total Cost
$83,386
Indirect Cost
$34,906
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
Research Institutes
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Gonzalez, Brian D; Hoogland, Aasha I; Kasting, Monica L et al. (2018) Psychosocial impact of BRCA testing in young Black breast cancer survivors. Psychooncology 27:2778-2785
Akuffo, Afua A; Alontaga, Aileen Y; Metcalf, Rainer et al. (2018) Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon. J Biol Chem 293:6187-6200
Mahajan, Nupam P; Coppola, Domenico; Kim, Jongphil et al. (2018) Blockade of ACK1/TNK2 To Squelch the Survival of Prostate Cancer Stem-like Cells. Sci Rep 8:1954
Rounbehler, Robert J; Berglund, Anders E; Gerke, Travis et al. (2018) Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiol Biomarkers Prev 27:1376-1383
Christy, Shannon M; Schmidt, Alyssa; Wang, Hsiao-Lan et al. (2018) Understanding Cancer Worry Among Patients in a Community Clinic-Based Colorectal Cancer Screening Intervention Study. Nurs Res 67:275-285
Chang, James M; Kosiorek, Heidi E; Dueck, Amylou C et al. (2018) Stratifying SLN incidence in intermediate thickness melanoma patients. Am J Surg 215:699-706
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
Sun, X; Ren, Y; Gunawan, S et al. (2018) Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia 32:1246-1249
Porubsky, Caitlin; Teer, Jamie K; Zhang, Yonghong et al. (2018) Genomic analysis of a case of agminated Spitz nevi and congenital-pattern nevi arising in extensive nevus spilus. J Cutan Pathol 45:180-183
Zhu, Genyuan; Nemoto, Satoshi; Mailloux, Adam W et al. (2018) Induction of Tertiary Lymphoid Structures With Antitumor Function by a Lymph Node-Derived Stromal Cell Line. Front Immunol 9:1609

Showing the most recent 10 out of 1254 publications